- Home
- ACIU vs ZURA Comparison
ACIU vs ZURA Comparison
Compare ACIU & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- ZURA
- Stock Information
- Founded
- ACIU 2003
- ZURA 2022
- Country
- ACIU Switzerland
- ZURA United States
- Employees
- ACIU N/A
- ZURA N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACIU Health Care
- ZURA Health Care
- Exchange
- ACIU Nasdaq
- ZURA Nasdaq
- Market Cap
- ACIU 213.3M
- ZURA 69.9M
- IPO Year
- ACIU 2016
- ZURA N/A
- Fundamental
- Price
- ACIU $2.46
- ZURA $1.92
- Analyst Decision
- ACIU Strong Buy
- ZURA Buy
- Analyst Count
- ACIU 2
- ZURA 10
- Target Price
- ACIU $10.00
- ZURA $12.67
- AVG Volume (30 Days)
- ACIU 136.3K
- ZURA 292.6K
- Earning Date
- ACIU 11-04-2025
- ZURA 11-06-2025
- Dividend Yield
- ACIU N/A
- ZURA N/A
- EPS Growth
- ACIU N/A
- ZURA N/A
- EPS
- ACIU N/A
- ZURA N/A
- Revenue
- ACIU $36,362,036.00
- ZURA N/A
- Revenue This Year
- ACIU N/A
- ZURA N/A
- Revenue Next Year
- ACIU $1,022.98
- ZURA N/A
- P/E Ratio
- ACIU N/A
- ZURA N/A
- Revenue Growth
- ACIU 86.71
- ZURA N/A
- 52 Week Low
- ACIU $1.43
- ZURA $0.97
- 52 Week High
- ACIU $3.98
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- ACIU 60.59
- ZURA 49.48
- Support Level
- ACIU $2.35
- ZURA $1.88
- Resistance Level
- ACIU $2.59
- ZURA $2.19
- Average True Range (ATR)
- ACIU 0.15
- ZURA 0.13
- MACD
- ACIU 0.03
- ZURA -0.04
- Stochastic Oscillator
- ACIU 75.89
- ZURA 7.50
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.